Oxaceprol PCD Pharma Franchise Company

Cafoli Lifecare offers Oxaceprol within its orthopaedic portfolio, with 3 formulations available as tablets and capsules. All products are manufactured at WHO-GMP certified, DCGI-approved facilities and offered to PCD franchise partners with exclusive district-wise monopoly rights.

What is Oxaceprol?

Oxaceprol is an atypical anti-inflammatory agent used in osteoarthritis. Unlike conventional NSAIDs, it does not act by inhibiting cyclo-oxygenase and prostaglandin synthesis; it is a derivative of hydroxyproline and is understood to work at the level of the joint by interfering with leukocyte adhesion and migration into inflamed tissue, thereby reducing the inflammatory cascade within the joint. Because it spares the prostaglandin pathway, it is generally associated with better gastrointestinal tolerability than classical NSAIDs. Compound data is available on PubChem.

Available Oxaceprol Formulations

The Cafoli Lifecare Oxaceprol range comprises 3 formulations in the following dosage forms:

• Tablets
• Capsules

Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Oxaceprol price list.

Therapeutic Applications of Oxaceprol

Prescribed under medical supervision for:

• Osteoarthritis of the knee, hip and other large joints
• Degenerative joint disease requiring long-term anti-inflammatory management
• Patients with osteoarthritis in whom prolonged conventional NSAID use is undesirable

Prescriber specialties: orthopaedic surgeons, rheumatologists and consulting physicians. Oxaceprol is a prescription-only medicine.

Why Oxaceprol is a High-Potential Molecule for Distributors

Osteoarthritis is one of the largest chronic-disease burdens in India and it is growing with the ageing population — but it is a therapy area with a structural problem: the NSAIDs that relieve it cannot safely be taken for years, especially by the elderly patients who need them most. Oxaceprol exists precisely in that gap, and that is the whole commercial argument for carrying it. Because it is prescribed for long-term, continuous use rather than a short pain course, each patient initiated represents months of repeat sales rather than a single strip. It also sits in a far less crowded and less price-eroded niche than the commodity analgesic shelf, where dozens of brands compete on rate alone. For a distributor already calling on orthopaedic surgeons — a small, concentrated and easily covered prescriber group in any district — Oxaceprol adds a differentiated, chronic, higher-margin line to a portfolio otherwise dominated by acute-pain SKUs.

Why Choose Cafoli Lifecare

• Monopoly rights — exclusive district-wise marketing rights for the Oxaceprol range
• WHO-GMP certified manufacturing and DCGI-approved products
• Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
• 1000+ franchise partners across India with an on-time dispatch record
• Transparent net rates and dedicated franchise support

References

1. PubChem — Oxaceprol compound record
2. PubMed — Oxaceprol in osteoarthritis
3. MedlinePlus — Osteoarthritis